Advaxis, Inc. (ADXS): Price and Financial Metrics


Advaxis, Inc. (ADXS)

Today's Latest Price: $0.71 USD

0.00 (0.00%)

Updated Jun 2 9:11am

Add ADXS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

ADXS Stock Summary

  • With a price/sales ratio of 35.7, Advaxis Inc has a higher such ratio than 95.55% of stocks in our set.
  • Revenue growth over the past 12 months for Advaxis Inc comes in at -94.94%, a number that bests only 0.78% of the US stocks we're tracking.
  • Advaxis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -79.99%, greater than the shareholder yield of only 5.68% of stocks in our set.
  • Stocks that are quantitatively similar to ADXS, based on their financial statements, market capitalization, and price volatility, are AKBA, ONTX, NOVN, MVIS, and SNSS.
  • Visit ADXS's SEC page to see the company's official filings. To visit the company's web site, go to www.advaxis.com.
ADXS Daily Price Range
ADXS 52-Week Price Range

ADXS Stock Price Chart More Charts


ADXS Price/Volume Stats

Current price $0.71 52-week high $2.95
Prev. close $0.71 52-week low $0.21
Day low $0.71 Volume 13,396
Day high $0.71 Avg. volume 3,813,180
50-day MA $0.65 Dividend yield N/A
200-day MA $0.61 Market Cap 42.77M

Advaxis, Inc. (ADXS) Company Bio


Advaxis Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. The company was founded in 2002 and is based in Princeton, New Jersey.


ADXS Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ADXS Latest Social Stream


Loading social stream, please wait...

View Full ADXS Social Stream

Latest ADXS News From Around the Web

Below are the latest news stories about Advaxis Inc that investors may wish to consider to help them evaluate ADXS as an investment opportunity.

Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020

PRINCETON, N.J., June 01, 2020 -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy.

Yahoo | June 1, 2020

Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC

Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced updated clinical and biomarker results from the monotherapy and combination arms of the Company’s ongoing Phase 1/2 study investigating ADXS-503 in patients with non-small cell lung cancer (NSCLC). The trial is evaluating ADXS-503, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

Yahoo | May 14, 2020

Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

PRINCETON, N.J., March 13, 2020 -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy.

Yahoo | March 13, 2020

Advaxis to Present at the 2020 LD Micro Virtual Conference

Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis will present at the third annual LD Micro Virtual Conference on March 4, 2020. Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.

Yahoo | March 3, 2020

Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced updated results from the combination arms of the Company’s ongoing Phase 1/2 study investigating ADXS-503 in patients with non-small cell lung cancer (NSCLC) at the Immuno-oncology 360° Conference in New York, New York. The trial is evaluating ADXS-503, part of the Company’s ADXS-HOT cancer-type specific immunotherapy program which leverages Advaxis’ proprietary Lm technology platform to target hotspot mutations that commonly occur in specific cancer types as well as other proprietary, tumor-associated antigens, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

Yahoo | February 27, 2020

Read More 'ADXS' Stories Here

ADXS Price Returns

1-mo 9.23%
3-mo -17.44%
6-mo 12.70%
1-year -73.41%
3-year -99.41%
5-year -99.83%
YTD -17.22%
2019 -69.91%
2018 -93.31%
2017 -60.34%
2016 -28.83%
2015 25.59%

Continue Researching ADXS

Here are a few links from around the web to help you further your research on Advaxis Inc's stock as an investment opportunity:

Advaxis Inc (ADXS) Stock Price | Nasdaq
Advaxis Inc (ADXS) Stock Quote, History and News - Yahoo Finance
Advaxis Inc (ADXS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0532 seconds.